Table 3.
Change from Baseline in Various Additional Cognitive Tests After 8 Weeks of Vortioxetine or Duloxetine Treatment (Standardized Effect Size Versus Placebo)
| Cognitive test | Mahableshwarkar et al., 2015 | McIntyre et al., 2014 | Katona et al., 2012 | |||
|---|---|---|---|---|---|---|
|
Vortioxetine
10/20 mg (n = 175) |
Duloxetine
60 mg (n = 187) |
Vortioxetine
10 mg (n = 193) |
Vortioxetine
20 mg (n = 204) |
Vortioxetine
5 mg (n = 152) |
Duloxetine
60 mg (n = 144) |
|
| Paper-and-pencil tests | ||||||
| TMT-A | 0.08 | 0.11 | 0.28** | 0.29** | – | – |
| TMT-B | 0.38* | 0.22 | 0.28** | 0.31** | – | – |
| STROOP congruent | –0.08 | 0.01 | 0.32** | 0.33** | – | – |
| STROOP incongruent | 0 | 0.09 | 0.33** | 0.31** | – | – |
| RAVLT acquisition | – | – | 0.26*† | 0.14† | 0.27* | 0.33** |
| RAVLT delayed recall | – | – | 0.32** | 0.28** | 0.24* | 0.32** |
| Computerized tests | ||||||
| SRT | 0.16 | 0.06 | 0.42*** | 0.24* | – | – |
| CRT | 0.18 | 0.09 | 0.36*** | 0.10 | – | – |
| GMLT | 0.11 | 0.10 | – | – | – | – |
| OBT | 0.08 | 0.04 | – | – | – | – |
*p < 0.05; **p < 0.01; ***p < 0.001 vs placebo. All p-values are nominal unless stated otherwise. † p-value not nominal.
CRT, Choice Reaction Time; DSST, Digital Symbol Substitution Test; GMLT, Groton Maze Learning Test; OBT, One-back Test; RAVLT, Rey Auditory Verbal Learning Test; SRT, Simple Reaction Time; STROOP, Stroop Color Naming Test; TMT-A/B, Trail Making Tests A and B.